As shown in Supplemental Fig. S8, KRAS mutations were detected in 8/17 samples (47.1%) of locally advanced cancer, 4/12 samples (33.3%) of peritoneal or lymph node metastasis, and 14/17 samples (82.3%) of liver or lung metastasis. This evidence concerns the gene KRAS and metastatic malignant neoplasm in the lymph nodes.